Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$19.72 - $28.68 $205,679 - $299,132
-10,430 Reduced 41.9%
14,462 $397,000
Q3 2023

Oct 26, 2023

SELL
$22.33 - $29.92 $6,475 - $8,676
-290 Reduced 1.15%
24,892 $555,000
Q2 2023

Aug 10, 2023

BUY
$20.96 - $26.99 $98,407 - $126,718
4,695 Added 22.92%
25,182 $641,000
Q4 2022

Feb 08, 2023

BUY
$15.31 - $29.94 $4,776 - $9,341
312 Added 1.55%
20,487 $486,000
Q1 2022

May 05, 2022

SELL
$21.94 - $42.51 $1,053 - $2,040
-48 Reduced 0.24%
20,175 $556,000
Q4 2021

Feb 04, 2022

BUY
$36.09 - $53.79 $3,464 - $5,163
96 Added 0.48%
20,223 $833,000
Q3 2021

Nov 08, 2021

SELL
$35.62 - $52.97 $1,032 - $1,536
-29 Reduced 0.14%
20,127 $935,000
Q1 2021

May 13, 2021

SELL
$44.47 - $81.38 $41,801 - $76,497
-940 Reduced 4.46%
20,156 $1.08 Million
Q4 2020

Feb 12, 2021

SELL
$32.49 - $61.88 $258,490 - $492,317
-7,956 Reduced 27.39%
21,096 $1.03 Million
Q3 2020

Nov 13, 2020

SELL
$26.73 - $35.67 $130,201 - $173,748
-4,871 Reduced 14.36%
29,052 $944,000
Q2 2020

Aug 13, 2020

SELL
$19.49 - $28.11 $28,007 - $40,394
-1,437 Reduced 4.06%
33,923 $879,000
Q1 2020

May 15, 2020

BUY
$16.13 - $30.17 $149,525 - $279,675
9,270 Added 35.53%
35,360 $860,000
Q3 2019

Nov 12, 2019

SELL
$23.87 - $30.93 $125,508 - $162,629
-5,258 Reduced 16.77%
26,090 $626,000
Q2 2019

Aug 08, 2019

SELL
$22.1 - $28.56 $113,881 - $147,169
-5,153 Reduced 14.12%
31,348 $894,000
Q1 2019

May 07, 2019

SELL
$12.0 - $25.76 $161,112 - $345,853
-13,426 Reduced 26.89%
36,501 $913,000
Q4 2018

Feb 05, 2019

BUY
$9.15 - $14.85 $29,865 - $48,470
3,264 Added 6.99%
49,927 $628,000
Q3 2018

Nov 09, 2018

BUY
$9.55 - $12.64 $445,631 - $589,820
46,663 New
46,663 $446,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.97B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Affinity Investment Advisors, LLC Portfolio

Follow Affinity Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Investment Advisors, LLC with notifications on news.